Formulation for the prevention of cardiovascular disease
OwnerNicholas J. Wald, Malcolm R. Lawinventors
Life of this patent
Estimating the term…
Abstract
This invention relates to a method for the prevention of cardiovascular disease, a formulation for the prevention of cardiovascular disease, the use of specified active principals for the manufacture of such a formulation for use in the method and to a method of preparing said formulation. The formulation of the present invention is a combination of active principals for use in the prevention of cardiovascular disease, notably ischaemic heart disease (including heart attacks) and stroke among the general adult population.
Claims17
1-40. (canceled)
A formulation comprising at least two drugs from the category of blood pressure lowering agents, each selected from a different physiological mode of action selected from a diuretic, a beta blocker, an angiotensin converting enzyme (ACE) inhibitor, an angiotensin II receptor antagonist, and a calcium channel blocker, and drugs from at least two of the following three categories:
- i) at least one lipid-regulating agent,
- ii) at least one platelet function altering agent, and
- iii) at least one serum homocysteine lowering agent.
A formulation comprising at least one drug from the category of blood pressure lowering agents independently selected from a diuretic, a beta blocker, an angiotensin converting enzyme (ACE) inhibitor, an angiotensin II receptor antagonist, and a calcium channel blocker and drugs from at least two of the following three categories:
- i) at least one lipid-regulating agent,
- ii) at least one platelet function altering agent, and
- iii) at least one serum homocysteine lowering agent,
- wherein the dose of the blood pressure lowering agent is below a recommended lower therapeutic dosage for the blood pressure lowering agent.
A formulation comprising at least two drugs from the category of blood pressure lowering agents independently selected from a diuretic, a beta blocker, an angiotensin converting enzyme (ACE) inhibitor, an angiotensin II receptor antagonist, and a calcium channel blocker and drugs from at least one of the following three categories:
- i) at least one lipid-regulating agent,
- ii) at least one platelet function altering agent, and
- iii) at least one serum homocysteine lowering agent,
- wherein the dose of the blood pressure lowering agent is below a recommended lower therapeutic dosage for the blood pressure lowering agent.
A formulation, comprising:
- i) about 12.5 mg hydrochlorothiazide, about 25 mg atenolol, and about 5 mg enalapril as blood pressure lowering agents,
- ii) from about 10 mg atorvastatin as a lipid-regulating agent,
- iii) about 75 mg aspirin as a platelet function altering agent, and
- iv) about 0.8 mg folic acid as a serum homocysteine lowering agent;
- wherein each specified dose is the daily dose.
A formulation, comprising:
- i) about 12.5 mg hydrochlorothiazide, about 25 mg atenolol, and about 5 mg enalapril as blood pressure lowering agents,
- ii) about 10-20 mg simvastatin as a lipid-regulating agent,
- iii) about 75 mg aspirin as a platelet function altering agent, and
- iv) about 0.8 mg folic acid as a serum homocysteine lowering agent;
- wherein each specified dose is the daily dose.
A formulation, comprising:
- i) about 12.5 mg hydrochlorothiazide, about 25 mg atenolol, and about 5 mg enalapril as blood pressure lowering agents,
- ii) from about 10 mg atorvastatin as a lipid-regulating agent,
- iii) about 0.8 mg folic acid as a serum homocysteine lowering agent;
- wherein each specified dose is the daily dose.
A formulation, comprising:
- i) about 12.5 mg hydrochlorothiazide, about 25 mg atenolol, and about 5 mg enalapril as blood pressure lowering agents,
- ii) about 10-20 mg simvastatin as a lipid-regulating agent,
- iii) about 0.8 mg folic acid as a serum homocysteine lowering agent;
- wherein each specified dose is the daily dose.
Dependencies are inferred from the claim text.